Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease

Journal of Clinical Psychopharmacology

Volumn 22, Issue 6, 2002, Pages 615-620

  Kaasinen, Valtteri ^a   Någren, Kjell ^b   Järvenpää, Tarja ^b   Roivainen, Anne ^b   Yu, Meixiang ^b   Oikonen, Vesa ^b   Kurki, Timo ^a   Rinne, Juha O ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU PET CENTRE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CARBON 11; DONEPEZIL; N METHYLPIPERIDYL 4 ACETATE C 11; RIVASTIGMINE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BEHAVIOR; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FRONTAL CORTEX; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL CORTEX;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; CARBAMATES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRONTAL LOBE; HUMAN; INDANS; MAGNETIC RESONANCE IMAGING; MALE; PARIETAL LOBE; PIPERIDINES; REPRODUCIBILITY OF RESULTS; SUPPORT, NON-U.S. GOV'T; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036897310     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200212000-00012     Document Type: Article

References (21)

1. Farlow MR, Evans RM. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998;51[suppl 1]:S36-44.
2. Giacobini E. Cholinergic foundations of Alzheimer's disease therapy. J Physiol (Paris) 1998;92:283-7.
3. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000;48:391-5.
4. Shinotoh H, Aotsuka A, Fukushi K, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured with PET. Neurology 2001;56:408-10.
5. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998;97:244-50.
6. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
7. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-9.
8. Lewellen TK, Kohlmyer SG, Miyaoka RS, et al. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 1996;43:2199-206.
9. van den Hoff J, Burchert W, Müller-Schauenburg W, et al. Accurate local blood flow measurements with dynamic PET: Fast determination of input function delay and dispersion by multilinear minimization. J Nucl Med 1993;34:1770-7.
10. Pellizzari CA, Chen GTY, Spelbring DR, et al. Accurate threedimensional registration of CT, PET, and/or MR images of the brain. J Comp Assist Tomogr 1989;13:20-6.
11. Namba H, Iyo M, Fukushi K, et al. Human cerebral acetylcholinesterase activity measured with positron emission tomography: Procedure, normal values and effect of age. Eur J Nucl Med 1999;26:135-43.
12. Herholz K, Bauer B, Wienhard K, et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: Comparison with blood flow and glucose metabolism. J Neural Transm 2000;107:1457-68.
13. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 1999;45[suppl 1]:15-22.
14. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-61.
15. Mesulam M. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In: Giacobini E, ed. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000:121-37.
16. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software.
17. Ogura H, Kosasa T, Kuriya Y, et al. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000;22:609-13.
18. Giacobini E. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy. In Giacobini E, ed. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000:181-226.
19. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
20. Sramek JJ, Cutler NR. RBC cholinesterase inhibition: A useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer Dis Assoc Disord 2000;14:216-27.
21. Kasa P, Papp H, Kasa P, et al. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzymepositive structures in the human and rat brain. Neuroscience 2000;101:89-100.